Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + stavudine (Medical Research Council)
- Development stage
- Unknown
- Lead developer
- Cipla
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lamivir-S is a fixed-dose combination antiretroviral medication containing lamivudine (3TC) and stavudine (d4T), both of which are nucleoside reverse transcriptase inhibitors (NRTIs). Developed by Cipla and evaluated in clinical trials such as the CHAPAS-1 pediatric HIV trial in Zambia (supported by the Medical Research Council), Lamivir-S is used in the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the viral reverse transcriptase enzyme, thereby blocking the replication of HIV-1. In pediatric settings, it has been utilized as part of a dose-escalation strategy alongside nevirapine to minimize early side effects like rash while maintaining therapeutic levels of the nucleoside backbone.
- Brand names
- Lamivir-SLamivir S
- Other names
- lamivudine/stavudinestavudine/lamivudined4T/3TC3TC/d4T
02
Targets
POLB (DNA polymerase beta)POLA1 (DNA polymerase alpha)HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptaseHIV-2 reverse transcriptasePOLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on lamivudine + stavudine (Medical Research Council).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + stavudine (Medical Research Council).